Yang ML, Doyle HA, Clarke SG, Herold KC, Mamula MJ: Oxidative Modifications in Tissue Pathology and Autoimmune Disease. Antioxid Redox Signal. 2017 Dec 11; 2017 Dec 11. PMID: 29088923

Gülden E, Palm N, Herold KC: MAIT Cells: A Link between Gut Integrity and Type 1 Diabetes. Cell Metab. 2017 Dec 5. PMID: 29211981

Naushad N, Perdigoto AL, Rui J, Herold KC: Have we pushed the needle for treatment of Type 1 diabetes? Curr Opin Immunol. 2017 Dec; 2017 Oct 6. PMID: 28992525

Gülden E, Vudattu NK, Deng S, Preston-Hurlburt P, Mamula M, Reed JC, Mohandas S, Herold BC, Torres R, Vieira SM, Lim B, Herazo-Maya JD, Kriegel M, Goodman AL, Cotsapas C, Herold KC: Microbiota control immune regulation in humanized mice. JCI Insight. 2017 Nov 2; 2017 Nov 2. PMID: 29093268

Ogura M, Deng S, Preston-Hurlburt P, Ogura H, Shailubhai K, Kuhn C, Weiner HL, Herold KC: Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017 Oct; 2017 Jul 21. PMID: 28739191

Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, Herold KC, Wen L, Flavell RA: Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proc Natl Acad Sci U S A. 2017 Sep 26; 2017 Sep 11. PMID: 28894001

Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM: Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol. 2017 Sep; 2017 Aug 18. PMID: 28844471

Bellin MD, Clark P, Usmani-Brown S, Dunn TB, Beilman GJ, Chinnakotla S, Pruett TL, Ptacek P, Hering BJ, Wang Z, Gilmore T, Wilhelm JJ, Hodges JS, Moran A, Herold KC: Unmethylated Insulin DNA Is Elevated After Total Pancreatectomy With Islet Autotransplantation: Assessment of a Novel Beta Cell Marker. Am J Transplant. 2017 Apr; 2016 Oct 24. PMID: 27643615

Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC: β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice. Cell Metab. 2017 Mar 7; 2017 Feb 9. PMID: 28190773

Mesquita PMM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC: Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection. J Infect Dis. 2017 Feb 15. PMID: 28007920

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J, Type 1 Diabetes TrialNet Study Group.: GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia. 2017 Jan; 2016 Oct 4. PMID: 27704166

Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS: Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol. 2016 Nov; 2016 Nov 18. PMID: 28664195

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC, Type 1 Diabetes TrialNet Study Group.: The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. J Immunol. 2016 Oct 15; 2016 Sep 21. PMID: 27655844

Herrin M, Tate JP, Akgün KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Ruser CB, Herold KC, Justice AC: Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr. 2016 Oct 1. PMID: 27171741

Garyu JW, Meffre E, Cotsapas C, Herold KC: Progress and challenges for treating Type 1 diabetes. J Autoimmun. 2016 Jul; 2016 May 17. PMID: 27210268

Wilcox NS, Rui J, Hebrok M, Herold KC: Life and death of β cells in Type 1 diabetes: A comprehensive review. J Autoimmun. 2016 Jul; 2016 Mar 24. PMID: 27017348

Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC: Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. Diabetes Care. 2016 Jun; 2016 Apr 13. PMID: 27208317

Garyu JW, Uduman M, Stewart A, Rui J, Deng S, Shenson J, Staron MM, Kaech SM, Kleinstein SH, Herold KC: Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE. J Biol Chem. 2016 May 20; 2016 Mar 18. PMID: 26994137

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT: A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Diabetes. 2016 May; 2015 Dec 30. PMID: 26718498

Rui J, Deng S, Lebastchi J, Clark PL, Usmani-Brown S, Herold KC: Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice. Diabetologia. 2016 May; 2016 Feb 24. PMID: 26910463

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC: Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol. 2016 Jan; 2015 Dec 14. PMID: 26518356

Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E: Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest. 2016 Jan; 2015 Dec 7. PMID: 26642366

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC: Inducing and Administering Tregs to Treat Human Disease. Front Immunol. 2015; 2016 Jan 22. PMID: 26834735

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q: Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25. PMID: 26606968

Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S, Herold KC, Kuchroo VK, Kleinewietfeld M, Hafler DA: Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest. 2015 Nov 2; 2015 Oct 20. PMID: 26524592

Herold KC, Majzoub JA, Melmed S, Pendergrass M, Schlumberger M: Endocrinology research-reflecting on the past decade and looking to the next. Nat Rev Endocrinol. 2015 Nov; 2015 Oct 13. PMID: 26460340

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group.: Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct. PMID: 26404927

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG: Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct. PMID: 26404926

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.: The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes Care. 2015 May; 2015 Mar 10. PMID: 25758770

Reed JC, Herold KC: Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol. 2015 May; 2015 Jan 27. PMID: 25623120

Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC: Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015 Apr. PMID: 25805871

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP, Type 1 Diabetes TrialNet Study Group.: β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015 Mar 2; 2015 Feb 2. PMID: 25642774

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP, Type 1 Diabetes TrialNet Study Group., Diabetes Prevention Trial-Type 1 Study Group.: A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care. 2015 Feb; 2014 Dec 17. PMID: 25519451

Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M: Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology. 2014 Sep; 2014 Jul 8. PMID: 25004096

Tooley JE, Herold KC: Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes. 2014 Aug. PMID: 24937037

Fadel TR, Sharp FA, Vudattu N, Ragheb R, Garyu J, Kim D, Hong E, Li N, Haller GL, Pfefferle LD, Justesen S, Herold KC, Fahmy TM: A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol. 2014 Aug; 2014 Aug 3. PMID: 25086604

Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC: Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol. 2014 Jul 15; 2014 Jun 18. PMID: 24943216

Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, Ruddle NH, Herold KC, Bothwell AL: A humanized mouse model of autoimmune insulitis. Diabetes. 2014 May; 2014 Jan 29. PMID: 24478396

Akirav EM, Henegariu O, Preston-Hurlburt P, Schmidt AM, Clynes R, Herold KC: The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma. PLoS One. 2014; 2014 Apr 23. PMID: 24759895

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.: Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 2014 Apr; 2014 Feb 18. PMID: 24550217

Vudattu NK, Herold KC: Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther. 2014 Mar. PMID: 24517093

Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC: Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev. 2014 Feb. PMID: 24115337

Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, Glaser B, Dor Y: Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Cell Metab. 2014 Jan 7; 2013 Dec 12. PMID: 24332968

Ghazi T, Rink L, Sherr JL, Herold KC: Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 2014; 2013 Aug 12. PMID: 23939544

Daifotis AG, Koenig S, Chatenoud L, Herold KC: Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol. 2013 Dec; 2013 May 11. PMID: 23726024

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.: Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes. 2013 Dec; 2013 Jul 17. PMID: 23863814

Herold KC: Restoring immune balance in type 1 diabetes. Lancet Diabetes Endocrinol. 2013 Dec; 2013 Sep 23. PMID: 24622404

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team.: Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 2013 Jul 8. PMID: 23835333

Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J, Protégé Trial Investigators.: Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013 Nov; 2013 Jun 25. PMID: 23801579

Vudattu NK, Herold KC: Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance. Immunotherapy. 2013 Nov. PMID: 24188671

Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, Herold KC, Hafler DA, O'Connor KC, Meffre E: Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013 Jun; 2013 May 15. PMID: 23676463

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group., Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group.: Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 1; 2013 Apr 5. PMID: 23562090

Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC: Immune therapy and β-cell death in type 1 diabetes. Diabetes. 2013 May; 2013 Feb 19. PMID: 23423576

Herold KC, Vignali DA, Cooke A, Bluestone JA: Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr. PMID: 23524461

Hughes JW, Herold KC: Novel SIRT1 mutation linked to autoimmune diabetes in humans. Cell Metab. 2013 Mar 5. PMID: 23473025

Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA: Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 2012 Oct 21. PMID: 23086558

Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, Hui P, McClaskey J, Hagopian WA, Meffre E, Marks PW, Wen L, Herold KC: Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma. J Clin Endocrinol Metab. 2012 Dec; 2012 Oct 16. PMID: 23074233

Waldron-Lynch F, Deng S, Preston-Hurlburt P, Henegariu O, Herold KC: Analysis of human biologics with a mouse skin transplant model in humanized mice. Am J Transplant. 2012 Oct; 2012 Aug 17. PMID: 22900715

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group.: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012 Aug; 2012 Jun 11. PMID: 22688329

Lebastchi J, Herold KC: Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med. 2012 Jun. PMID: 22675665

Sosenko JM, Skyler JS, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.: The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 2012 Jun. PMID: 22618768

Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, Skovronsky DM, Herold KC, McCarthy TJ, Calle RA, Carson RE, Treadway JL, Cline GW: In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med. 2012 Jun; 2012 May 9. PMID: 22573821

Tooley JE, Waldron-Lynch F, Herold KC: New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med. 2012 Mar; 2012 Feb 17. PMID: 22342807

Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC: Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med. 2012 Jan 25. PMID: 22277969

Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold KC: Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes. 2012 Jan; 2011 Oct 31. PMID: 22043003

Ablamunits V, Klebanov S, Giese SY, Herold KC: Functional human to mouse adipose tissue xenotransplantation. J Endocrinol. 2012 Jan; 2011 Oct 17. PMID: 22007021

Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC: RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One. 2012; 2012 Apr 11. PMID: 22509345

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, Type 1 Diabetes TrialNet Study Group.: Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011 Dec; 2011 Sep 9. PMID: 21908031

Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC: Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A. 2011 Nov 22; 2011 Nov 9. PMID: 22074781

Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM, Type 1 Diabetes TrialNet Anti-CD20 Study Group.: Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol. 2011 Aug 15; 2011 Jul 20. PMID: 21775681

Herold KC, Bluestone JA: Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med. 2011 Aug 10. PMID: 21832236

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Protégé Trial Investigators.: Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6; 2011 Jun 28. PMID: 21719095

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group.: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011 Jul 23; 2011 Jun 27. PMID: 21714999

Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W Jr, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA: Control of TH17 cells occurs in the small intestine. Nature. 2011 Jul 17; 2011 Jul 17. PMID: 21765430

Ablamunits V, Henegariu O, Preston-Hurlburt P, Herold KC: NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur J Immunol. 2011 Jul; 2011 Jun 6. PMID: 21538351

Waldron-Lynch F, Herold KC: Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov. 2011 Jun. PMID: 21629294

Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ: How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 2011 May. PMID: 21525508

Akirav EM, Baquero MT, Opare-Addo LW, Akirav M, Galvan E, Kushner JA, Rimm DL, Herold KC: Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes. 2011 Mar; 2011 Feb 9. PMID: 21307078

Kochar R, Herold KC: Prevention of T1DM: feeding the ultimate goal. Nat Rev Endocrinol. 2011 Mar; 2011 Feb 8. PMID: 21301485

Akirav EM, Ruddle NH, Herold KC: The role of AIRE in human autoimmune disease. Nat Rev Endocrinol. 2011 Jan; 2010 Nov 23. PMID: 21102544

Ablamunits V, Bisikirska B, Herold KC: Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct. PMID: 21038470

Luo X, Herold KC, Miller SD: Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 2010 Apr 23. PMID: 20412759

Cernea S, Herold KC: Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol. 2010 Feb. PMID: 19837003

Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, Type 1 Diabetes TrialNet Research Group.: Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 2009 Nov; 2009 Aug 12. PMID: 19675135

Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP, D-Cure Workshop.: Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev. 2009 Nov. PMID: 19771545

Begum S, Chen W, Herold KC, Papaioannou VE: Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology. 2009 Oct; 2009 Jul 9. PMID: 19589867

Lepus CM, Gibson TF, Gerber SA, Kawikova I, Szczepanik M, Hossain J, Ablamunits V, Kirkiles-Smith N, Herold KC, Donis RO, Bothwell AL, Pober JS, Harding MJ: Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol. 2009 Oct; 2009 Jun 12. PMID: 19524633

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group.: Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 2009 May 14. PMID: 19443276

Waldron-Lynch F, Herold KC: Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinol Metab Clin North Am. 2009 Jun. PMID: 19328413

Kaufman A, Herold KC: Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev. 2009 May. PMID: 19319985

Chen W, Begum S, Opare-Addo L, Garyu J, Gibson TF, Bothwell AL, Papaioannou VE, Herold KC: Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells. Endocrinology. 2009 Feb; 2008 Oct 9. PMID: 18845629

Waldron-Lynch F, Herold KC: Continuous glucose monitoring: long live the revolution! Nat Clin Pract Endocrinol Metab. 2009 Feb; 2008 Dec 17. PMID: 19092785

Ablamunits V, Bisikirska BC, Herold KC: Human regulatory CD8 T cells. Ann N Y Acad Sci. 2008 Dec. PMID: 19120302

Akirav E, Kushner JA, Herold KC: Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008 Nov. PMID: 18971435

Ablamunits V, Herold KC: Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Hum Immunol. 2008 Nov; 2008 Sep 24. PMID: 18817833

Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC: RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15. PMID: 18768885

Sherr J, Sosenko J, Skyler JS, Herold KC: Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab. 2008 Jun; 2008 Apr 29. PMID: 18446141

King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson MA, Wasserfall C, Herold KC, Woodland RT, Schmidt MR, Woda BA, Thompson MJ, Rossini AA, Greiner DL: A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol. 2008 Mar; 2007 Dec 21. PMID: 18096436

Waldron-Lynch F, von Herrath M, Herold KC: Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Found Symp. 2008. PMID: 19203097

Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE: A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab. 2007 Dec. PMID: 18026162

Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC: Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007 Nov; 2007 Aug 2. PMID: 17673522

Ablamunits V, Sherry NA, Kushner JA, Herold KC: Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci. 2007 Apr; 2007 Mar 21. PMID: 17376841

Moser B, Szabolcs MJ, Ankersmit HJ, Lu Y, Qu W, Weinberg A, Herold KC, Schmidt AM: Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant. 2007 Feb. PMID: 17241110

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group.: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2007 Jan. PMID: 17192330

Witkowski P, Herold KC: Islet transplantation for type 1 diabetes--where should we go? Nat Clin Pract Endocrinol Metab. 2007 Jan. PMID: 17179921

Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC: Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006 Dec. PMID: 17130466

Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC: Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep. PMID: 16936208

Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006 May; 2006 Apr 20. PMID: 16628253

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2006 Mar. PMID: 16505520

Tsai EB, Sherry NA, Palmer JP, Herold KC: The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006 Feb; 2006 Jan 11. PMID: 16404554

Cernea S, Herold KC: Drug insight: New immunomodulatory therapies in type 1 diabetes. Nat Clin Pract Endocrinol Metab. 2006 Feb. PMID: 16932263

Moser B, Herold KC, Schmidt AM: Receptor for advanced glycation end products and its ligands: initiators or amplifiers of joint inflammation--a bit of both? Arthritis Rheum. 2006 Jan. PMID: 16385492

Sherry NA, Tsai EB, Herold KC: Natural history of beta-cell function in type 1 diabetes. Diabetes. 2005 Dec. PMID: 16306337

Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC: TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct; 2005 Sep 15. PMID: 16167085

Chen W, Bluestone JA, Herold KC: Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005 Sep-Dec. PMID: 16318983

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA: A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun. PMID: 15919798

Bisikirska BC, Herold KC: Regulatory T cells and type 1 diabetes. Curr Diab Rep. 2005 Apr. PMID: 15794912

Rong LL, Gooch C, Szabolcs M, Herold KC, Lalla E, Hays AP, Yan SF, Yan SS, Schmidt AM: RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci. 2005. PMID: 16477098

Bisikirska BC, Herold KC: Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Ann N Y Acad Sci. 2004 Dec. PMID: 15699486

Siegel-Czarkowski L, Herold KC, Goland RS: Continuous subcutaneous insulin infusion in older patients with type 1 diabetes. Diabetes Care. 2004 Dec. PMID: 15562235

Glandt M, Herold KC: Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation. Curr Diab Rep. 2004 Aug. PMID: 15265472

Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, Stern D, Herold KC: Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004 Jul 15. PMID: 15240736

Herold KC: Treatment of type 1 diabetes mellitus to preserve insulin secretion. Endocrinol Metab Clin North Am. 2004 Mar. PMID: 15053897

Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC: Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb. PMID: 14747294

Herold KC: Achieving antigen-specific immune regulation. J Clin Invest. 2004 Feb. PMID: 14755329

Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004 Jan. PMID: 14693724

Glandt M, Hagopian W, Herold KC: Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Rev Endocr Metab Disord. 2003 Dec. PMID: 14618021

Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA: Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb. PMID: 12569167

Herold KC, Taylor L: Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol Res. 2003. PMID: 14610290

Fontaine MJ, Blanchard J, Rastellini C, Lazda V, Herold KC, Pollak R: Pancreatic islets activate portal vein endothelial cells in vitro. Ann Clin Lab Sci. 2002 Fall. PMID: 12458886

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30. PMID: 12037148

Herold KC: Hepatitis C virus infection. N Engl J Med. 2001 Nov 8. PMID: 11794187

Liu EH, Herold KC: Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus. Trends Endocrinol Metab. 2000 Nov. PMID: 11042469

Artwohl JE, Flynn JC, Bunte RM, Angen O, Herold KC: Outbreak of Pasteurella pneumotropica in a closed colony of STOCK-Cd28(tm1Mak) mice. Contemp Top Lab Anim Sci. 2000 Jan. PMID: 11178314

Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998 Jan 22. PMID: 9435328

Herold KC, Lu J, Rulifson I, Vezys V, Taub D, Grusby MJ, Bluestone JA: Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol. 1997 Nov 1. PMID: 9379007

Herold KC, Baumann E, Vezys V, Buckingham F: Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2d mice. J Autoimmun. 1997 Feb. PMID: 9080296

Herold KC, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone JA: CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1997 Jan 15. PMID: 8993020

Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 1996 Sep. PMID: 8808683

Herold KC, Vezys V, Sun Q, Viktora D, Seung E, Reiner S, Brown DR: Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996 May 1. PMID: 8617981

Baumann EE, Buckingham F, Herold KC: Intrathymic transplantation of islet antigen affects CD8+ diabetogenic T-cells resulting in tolerance to autoimmune IDDM. Diabetes. 1995 Aug. PMID: 7621990

O'Meara NM, Sturis J, Herold KC, Ostrega DM, Polonsky KS: Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 1995 Apr. PMID: 7497873

Herold KC, Bloch TN, Vezys V, Sun Q: Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells. Diabetes. 1995 Mar. PMID: 7883124

Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 Mar 1. PMID: 7532678

Herold KC, Vezys V, Gage A, Montag AG: Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol. 1994 Sep. PMID: 7915204

Alegre ML, Sattar HA, Herold KC, Smith J, Tepper MA, Bluestone JA: Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation. 1994 Jun 27. PMID: 8016885

Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF: Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation. 1993 Jan. PMID: 7678356

Nossal GJ, Herold KC, Goodnow CC: Autoimmune tolerance and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992 Dec. PMID: 1478378

Herold KC, Montag AG, Buckingham F: Induction of tolerance to autoimmune diabetes with islet antigens. J Exp Med. 1992 Oct 1. PMID: 1402656

Herold KC, Rubenstein AH: New directions in the immunology of autoimmune diabetes. Ann Intern Med. 1992 Sep 1. PMID: 1503336

Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R: Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 1992 Mar. PMID: 1532369

Herold KC, Polonsky KS: Does tight glucose control enhance brain sensitivity to low glucose? Diabetes Care. 1991 Feb. PMID: 2060418

Loeb JA, Herold KC, Barton KP, Robinson LE, Jaspan JB: Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care. 1989 Jun. PMID: 2659301

Herold KC, Kastern W, Markholst H, Lernmark A: Derivation of non-lymphopenic BB rats with an intercross breeding. Autoimmunity. 1989. PMID: 2577492

Herold KC, Rubenstein AH: Immunosuppression for insulin-dependent diabetes. N Engl J Med. 1988 Mar 17. PMID: 3344022

Herold KC, Lancki DW, Dunn DE, Arai K, Fitch FW: Activation of lymphokine genes during stimulation of cloned T cells. Eur J Immunol. 1986 Dec. PMID: 3102245

Herold KC, Jaspan JB: Hepatic glucagon clearance during insulin induced hypoglycemia. Horm Metab Res. 1986 Jul. PMID: 3527924

Moldwin RL, Lancki DW, Herold KC, Fitch FW: An antigen receptor-driven, interleukin 2-independent pathway for proliferation of murine cytolytic T lymphocyte clones. J Exp Med. 1986 Jun 1. PMID: 3486939

Herold KC, Lancki DW, Moldwin RL, Fitch FW: Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol. 1986 Feb 15. PMID: 2935576

Herold KC, Polonsky KS, Cohen RM, Levy J, Douglas F: Variable deterioration in cortical function during insulin-induced hypoglycemia. Diabetes. 1985 Jul. PMID: 3891475

Polonsky KS, Herold KC, Gilden JL, Bergenstal RM, Fang VS, Moossa AR, Jaspan JB: Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes. 1984 Nov. PMID: 6389228

Herold KC, Huen A, Gould L, Traisman H, Rubenstein AH: Alterations in lymphocyte subpopulations in type 1 (insulin-dependent) diabetes mellitus: exploration of possible mechanisms and relationships to autoimmune phenomena. Diabetologia. 1984 Jul. PMID: 6237011